000 04360nam a22004455c 4500
999 _c6430
_d6430
001 6430
003 ES-MaUEC
005 20200623133217.0
006 a||||fo|||| 00| 0
007 cr nn 008mamaa
008 181016s2019 gw a s |||| 0|eng d
020 _a9783319993508
024 7 _a10.1007/978-3-319-99350-8
_2doi
040 _bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aQP572
_b.E85 2019EB
245 0 0 _aEstrogen Receptor and Breast Cancer.
_bCelebrating the 60th Anniversary of the Discovery of ER
_cedited by Xiaoting Zhang.
264 1 _aCham
_bSpringer International Publishing :
_bImprint: Humana Press
_c2019.
300 _aXII, 417 páginas 79 ilustraciones, 69 ilustraciones a color
336 _2rdacontent
_aTexto (visual)
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _atext file
_bPDF
_2rda
490 1 _aCancer Drug Discovery and Development,
_x2196-9906
490 0 _aMedicine (Springer-11650)
505 0 _a1. Introduction: On the discovery of Estrogen Receptor -- 2. Physiological and Pathological Roles of Estrogen Receptor -- 3. Estrogen Receptor Cofactors -- 4. ER-Mediated Gene Transcription -- 5. ER Transcriptome -- 6. Estrogen Receptor Regulation of Non-Coding RNAs in Breast Cancer -- 7. First Targeted Therapy --- History of Tamoxifen -- 8. Selective Estrogen Receptor Modulators (SERMs) -- 9. New Estrogen Receptor Drugs -- 10. Endocrine Therapy in Clinical Practice -- 11. Structural Insights into ER and Anti-Estrogen Therapies -- 12. Molecular Mechanisms of Endocrine Resistance -- 13. Estrogen Receptor Mutants in Breast Cancer -- 14. Estrogen Receptor Beta and Isoforms in Breast Cancer -- 15. Xenoestrogens, Phytoestrogens and Breast Cancer -- 16. Emerging Approaches to Overcome Endocrine Resistance.
520 3 _aThe discovery of ER by Dr. Elwood Jensen exactly 60 years ago has not only led to the birth of a whole new vital nuclear receptor research field but also made a rapid, direct and lasting impact on the treatment and prevention of breast cancer. Since that landmark discovery, tremendous progress has been made in our understanding of the molecular functions of ER and development of targeted therapies against ER pathways for breast cancer treatment. However, there is currently no book available addressing these discoveries and recent advancement in a historical and systematic fashion. This book is intended to provide comprehensive, most up-to-date information on the history and recent advancement of ER and breast cancer by world renowned leaders in the field. These chapters include the history of the discovery of ER; physiological and pathological roles of ER; recent discovery of ER cistrome, transcriptome and its regulation of noncoding RNAs such as microRNAs and enhancer RNAs in breast cancer; development and clinical practices of the first targeted therapy Tamoxifen and other antiestrogens for breast cancer treatment; structural basis of ER and antiestrogen actions; molecular insights into endocrine resistance; the role of ER mutants, ER-beta and environmental estrogens in breast cancer; and emerging state-of-the-art therapeutic approaches currently in development to overcome treatment resistance and future perspectives. The book will provide undergraduate and graduate students, basic scientists and clinical cancer researchers, residents, fellows, as well as clinicians, oncology educators and the general public a thorough and authoritative review of these exciting topics.
988 _aPrimersemestre_2019_Medicine
650 1 4 _aCancer Research.
_0http://scigraph.springernature.com/things/product-market-codes/B11001
653 0 _aOncology.
653 0 _aMedicine.
700 1 _aZhang, Xiaoting.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
_9106937
776 0 8 _iPrinted edition:
_z9783319993492
776 0 8 _iPrinted edition:
_z9783319993515
776 0 8 _iPrinted edition:
_z9783030075934
830 0 _aCancer Drug Discovery and Development,
_x2196-9906
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-99350-8
_zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942 _2lcc
_cLE
998 _db
_feng
_ggw
_h0
_el